News

GENova Biotherapeutics (GENova) has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain

Pharmacyclics has reported a GAAP net loss of $5.4m, or $0.20 per share for the fourth quarter of fiscal 2009, compared to a net loss of $4.6m, or

Juvaris BioTherapeutics (Juvaris) has completed the first close on its Series B equity financing of up to $25m led by SV Life Sciences (SVLS) along with existing investor,

Regulus Therapeutics (Regulus), Alnylam and Isis Pharmaceuticals (Isis) have reported that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a

The US Patent & Trademark Office (PTO) has issued a “Notice of Allowance” in OSI Pharmaceuticals’ (OSI) reissue application for US Patent No 5747498 (the ‘498) composition of

Rexahn Pharmaceuticals (Rexahn) has reached an agreement to close on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical (Teva) for the development of its novel

Hyperion Therapeutics (Hyperion) has reported that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the FDA for intermittent or chronic treatment of patients with

Ranbaxy has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox, South Korea’s Botulinum -Toxin specialised Biotech Venture, for its cosmetic product, Neuronox. The introduction

China Aoxing Pharmaceutical (China Aoxing) has reported that its Clinical Trial Application (CTA) for Tilidine/Naloxone Capsules, an opioid drug with abuse resistance property, was officially approved by the